



The Brazilian Journal of INFECTIOUS DISEASES

www.elsevier.com/locate/bjid



Brief communication

Genetic analysis of the first *mcr-1* positive *Escherichia coli* isolate collected from an outpatient in Chile



Camila Gutiérrez^a, Javier Zenis^a, Paulette Legarraga^b, Jaime R. Cabrera-Pardo^c, Patricia García^b, Helia Bello-Toledo^a, Andrés Opazo-Capurro ^{a,d,*}, Gerardo González-Rocha^{a,d}

^a Universidad de Concepción, Facultad de Ciencias Biológicas, Departamento de Microbiología, Concepción, Chile

^b Pontificia Universidad Católica de Chile, Escuela de Medicina, Departamento de Laboratorios Clínicos, Santiago, Chile

^c Universidad del Bío-Bío, Facultad de Ciencias, Departamento de Química, Concepción, Chile

^d Millennium Nucleus on Interdisciplinary Approach to Antimicrobial Resistance (MICROB-R), Chile

ARTICLE INFO

Article history:

Received 3 January 2019

Accepted 19 May 2019

Available online 20 June 2019

Keywords:

Colistin-resistance

mcr-1

Escherichia coli

Chile

ABSTRACT

Global dissemination of *mcr*-like genes represents a serious threat to public health since it jeopardizes the effectiveness of colistin, an antibiotic used as a last-resort treatment against highly antibiotic-resistant bacteria. In 2017, a *mcr-1*-positive isolate of *Escherichia coli* was found in Chile for the first time. Herein we report the genetic features of this strain (UCO-457) by whole-genome sequencing (WGS) and conjugation experiments. The UCO-457 strain belonged to ST4204 and carried a 285 kb IncI2-type plasmid containing the *mcr-1* gene. Moreover, this plasmid was transferred by conjugation to an *E. coli* J53 strain at high frequency. The isolate harbored the *cma*, *iroN*, and *iss* virulence genes and did carry resistance genes to trimethoprim/sulfamethoxazole and fluoroquinolones. Other antibiotic resistance determinants such as β-lactamases-encoding genes were not detected, making the isolate highly susceptible to these antibiotics. Our results revealed that such susceptible isolates could be acting as platforms to disseminate plasmid-mediated colistin resistance. Based on this evidence, we consider that *mcr*-like prevalence deserves urgent attention and should be examined not only in highly resistant bacteria but also in susceptible isolates.

© 2019 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Colistin represents the last resort to treat serious infections caused by highly resistant Gram-negative pathogens, such as extensively drug-resistant (XDR) Enterobacteriaceae

and non-fermenting bacilli.¹ In late 2015, Liu et al. found a plasmid-borne *mcr-1* gene, which confers colistin resistance, in *Escherichia coli* and *Klebsiella pneumoniae* from diverse sources in China including food products, livestock, and humans.^{1,2} This was the first description of a colistin resistance trait harbored by a mobile genetic element, thus implicating the likely

* Corresponding author.

E-mail address: andopazo@udec.cl (A. Opazo-Capurro).

<https://doi.org/10.1016/j.bjid.2019.05.008>

1413-8670/© 2019 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

horizontal spread of colistin resistance. Indeed, *mcr* genes have since been described across the world from a myriad of sources including food products, animals, humans, and environmental samples.¹ In South America (SA), *mcr-1* has been identified in *Enterobacteriaceae* isolated from Argentina, Ecuador, Colombia, Bolivia, Venezuela, and Brazil. In addition, *mcr-5* has been reported in Brazil.^{3,4} So far, no other *mcr*-like genes have been identified in SA.

It is crucial to track the presence and dissemination of *mcr*-like genes since decreasing the effectiveness of colistin leaves no therapeutic option to tackle highly resistant Gram-negative bacteria. Unfortunately, data concerning colistin-resistance and prevalence of *mcr*-like genes in SA, and Chile in particular, are scant. To date, Legarraga et al.⁵ published the first and only clinical description of *mcr-1* in Chile, which was found in an *E. coli* isolate (UCO-457) recovered from a urinary infection in an outpatient of a hospital located in Santiago, Chile.⁵ The authors further described that this isolate was resistant to ciprofloxacin and trimethoprim/sulfamethoxazole, and susceptible to β -lactams, aminoglycosides and nitrofurantoin.

In order to achieve a fuller characterization of the first *mcr-1* positive *E. coli* strain, we aimed to carry out whole-genome sequencing (WGS) of the UCO-457 isolate and study the transferability of *mcr-1* by conjugation. Antimicrobial susceptibility profiles were determined by the disc diffusion method following the CLSI guidelines.⁶ The minimum inhibitory concentration (MIC) to colistin (CST) was determined by the broth dilution technique, and the results were interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST; <http://www.eucast.org/clinical.breakpoints>) guidelines. WGS was performed using the Illumina MiSeq platform with a coverage of 30 \times with 2 \times 250 bp paired-end reads. *De novo* assemblies were carried out by SPAdes v3.7 yielding 61 contigs (\geq 1000 bp). Species identification, sequence type (ST), serotype, Fim type, and plasmid replicon typing content were identified in silico using tools available at the Center for Genomic Epidemiology (CGE) server (<http://www.genomicepidemiology.org>). Virulence genes were investigated using the virulence finder tool of the CGE server and the Pathosystems Resources Integration Center (PATRIC) toolkit (<https://www.patricbrc.org/>). Antibiotic-resistance genes (ARGs) were screened using ResFinder (<http://cge.cbs.dtu.dk/services/ResFinder/>) and the Comprehensive Antibiotic Resistance Database (CARD) (<http://arpcard.mcmaster.ca>).

The total genome length was 4,947,619 bp, with a N₅₀ contig size of 210,597 bp and G + C content of 50.54%, consistent with other species in the *Escherichia* genus. This Whole Genome Shotgun project has been deposited at DDBJ/ENA/GenBank under the accession RXIT00000000. The version described in this manuscript is version RXIT00000000.1.

From the WGS data, we corroborated the identification of the isolate as *E. coli* using the SpeciesFinder tool on the CGE website. The isolate corresponded to ST4204 (CC10) according to the Warwick MLST scheme. Interestingly, *mcr-1*-positive isolates collected from urinary tract infections in China have also been associated to this ST.^{7,8} The plasmid containing the *mcr* gene in these isolates also carried the extended-spectrum β -lactamase gene *bla*_{CTX-M-55}, in which both resistance genes

were co-transferred by conjugation.^{7,8} The strain was negative for *bla*_{CTX-M}, consistent with its observed susceptibility to β -lactams.⁵

Likewise, in silico typing revealed that UCO-457 corresponded to the serotype O6:H10 and belonged to the subclone *fimH24*. This serotype has been previously defined as pathogenic, since it typically produces toxins.⁹ However, we did not detect any toxin-related genes, although we did find diverse virulence genes such as *cma* (accession n° FJ664752), *iroN* (accession n° AF449498) and *iss* (accession n° DQ381420). The *cma* gene encodes a colicin M protein, which corresponds to a bacteriocin,¹⁰ while *IroN* corresponds to a enterobactin siderophore receptor protein, which is considered to be a urovirulence factor.¹¹ Moreover, *iss* encodes a protein that increases the serum survival of *E. coli*, thus conferring resistance to the complement system.¹²

E. coli ST131 is a globally disseminated multidrug-resistant clone involved in urinary tract and bloodstream infections which possesses the type 1 fimbriae *fimH30* allele.¹³ As described above, UCO-457 harbored the *fimH24* subtype and thus is not related to the uropathogenic clone ST131. It is important to strengthen the national surveillance in Chile since there are not data about the *fim* subtypes circulating in the country. For instance, the *fimH24* subtype, which is largely unknown in Chile, has been associated to national outbreaks in Denmark.¹⁴

As expected, the WGS data analysis revealed the presence of the colistin-resistance gene *mcr-1*. Specifically, this gene was detected in a contig of 64,036 bp which did not contain any additional ARGs. Within the contig, *mcr-1* was delimited upstream by a gene that encodes a PAP2-family protein and downstream by a relaxase-encoding gene (Fig. 1). This genetic environment differs from that commonly associated to *mcr-1* in which the ISApI1-transposon is linked to this gene and mediates its dissemination.¹⁵ We detected the IncI2-repliscon sequence in the same 64,036 bp contig with *mcr-1*, but did not detect any ISApI1 elements surrounding the *mcr-1* gene (Fig. 1). This arrangement is reminiscent of the *mcr*-carrying *E. coli* from Argentina and Canada characterized by Tijet et al. where they found that the segment containing the *mcr-1* gene had the *pap2* and relaxase genes,¹⁶ as found in our isolate (Fig. 1). Moreover, some of the colistin-resistant *E. coli* isolates analyzed in their study also lacked the ISApI1 element. This could be explained by the mobilization of the IS resulting in the transfer of the *mcr-1-pap2* arrangement to a conjugative plasmid with consequent loss of ISApI1,¹⁶ a process that could also have occurred in UCO-457.

Among *Enterobacteriaceae*, *mcr-1* has been associated with many different incompatibility plasmid groups including IncI2, IncX4, IncHI1, IncHI2, IncFI, IncFII, IncP, IncI2-FIB, IncX1-X2, and IncX3-X4.¹⁷ Based on phylogenetic analysis, it has been suggested that IncI2 plasmids can migrate among different bacterial species with *E. coli* acting as a carrier of *mcr-1* between them.¹⁸ Interestingly, the *pap2-mcr-1* element has been previously detected in IncI2-plasmids.¹⁶ Although IncI2 plasmids are frequently associated with *bla*_{CTX-M-55} and *bla*_{KPC-3},¹⁸ these genes were not detected in UCO-457. These intriguing patterns warrant further study of the prevalence and potential role of this plasmid group in the dissemination of *mcr-1*.




Fig. 1 – Genetic environment of *mcr-1* in *E. coli* UCO-457. Genes and their transcriptional orientations are indicated by green arrows. This diagram was designed utilizing the 64,036 bp contig in which *mcr-1* was detected.

In addition to *mcr-1*, the *sul2* and *dfrA14* genes were identified explaining the resistance phenotype to trimethoprim/sulfamethoxazole. We found that the *IntI1* gene was in the same contig as *dfrA14*, suggesting this gene could be associated to a class 1 integron. This finding was confirmed by the NCBI Prokaryotic Genome Annotation Pipeline (PGAP),¹⁹ in which the *dfrA14* gene was located immediately downstream the integrase gene (GenBank accession number RXIT01000051.1). We did not find any genes associated with the 3' conserved region of these genetic elements, such as the *qacEΔ1* and *sul1*²⁰ elements, indicating that some rearrangements could be present in the structure of the detected integron.

The UCO-457 isolate had also been reported to be susceptible to amikacin and gentamicin and resistant to streptomycin. We detected the *aph(3'')-Ib* gene in the genome. This gene (also named as *strA*) mediates resistance specifically to streptomycin, explaining the observed phenotype.²¹ Finally, in addition to acquired resistance genes, we detected two-point mutations, S83L and D87N in *gyrA*, as well as a single point mutation S80I in *parC*, which are involved in resistance to ciprofloxacin.²²

In complement to the WGS analysis, the plasmid content of UCO-457 was determined by the alkaline lysis method followed by pulsed-field gel electrophoresis (PFGE). Pure DNA plasmid extracts were used to examine whether *mcr-1* was contained in this mobile element by PCR. Moreover, *mcr-1* transferability was studied by conjugation using the *E. coli* J53 strain (sodium azide resistant and colistin susceptible) as the recipient strain. Susceptibilities to β-lactams, aminoglycosides, nitrofurantoin and CST in addition to their isogenicity and the presence of *mcr-1* and IncI2-replicon were determined by the disk diffusion test, broth microdilution, ERIC-PCR and conventional PCR, respectively. From these studies, we detected a large plasmid of ca. 285 kb which contained the *mcr-1* and the IncI2 sequence in UCO-457, which were also detected in the transconjugant *E. coli* J53-MCR1. Additionally, we determined that the plasmid transfer occurred with a high frequency of 2.8×10^{-4} transconjugants per recipient. It is important to note that the Illumina platform generates short reads, making it difficult to determine the entire sequence of plasmids.²³ Due to the generation of these short reads, the use of Illumina to predict plasmids (i.e., by PlasmidFinder) is limited, being only possible to search for the incompatibility groups in the draft genome data generated from WGS.²³ As a

consequence, it is necessary to isolate and sequence the plasmid containing the *mcr-1* in UCO-457 in order to determine its complete sequence.

MIC to CST of *E. coli* J53 varied from 2 µg/mL (J53) to 8 µg/mL (J53-MCR1) after the mating experiments, reaching the same value as the donor strain. Notably, the susceptibility pattern of J53-MCR1 to other antibiotics was not altered, demonstrating that only *mcr-1* was transferred during this process. This finding confirms that the *mcr-1* gene was the only antibiotic-resistance gene transferable at a high frequency. Similar results were obtained by Tijet et al., in which they described that colistin was the only antibiotic for which the resulting transformant was resistant after conjugation from *mcr-1*-carrying *E. coli* as a donor.¹⁶ As the UCO-457 isolate was recovered from a urinary tract infection from an outpatient, it is difficult to track the further spread of *mcr-1* from this case. To the authors' knowledge, there have been no additional reports of *mcr*-like genes in Chile to date.

In conclusion, we characterized the first *mcr-1*-positive *E. coli* isolated in Chile and found it to be part of the CC10 identified in China. The *mcr-1* gene was detected in an IncI2-plasmid, which is known to be promiscuous. Therefore, further investigation is warranted in order to determine the prevalence and dissemination of this *mcr*-carrying plasmid. Finally, the isolate in which *mcr-1* was detected was highly susceptible to other antibiotics, highlighting the potential role for such isolates to act as platforms for the dissemination of *mcr* genes.

Conflicts of interest

The authors declare no conflicts of interest.

Funding source

Attraction and Insertion of Advanced Human Capital Program (PAI), CONICYT, Chile, under the project PAI79170082.

Acknowledgments

The authors want to thank the National Commission for Scientific and Technological Research of Chile (CONICYT), for supporting this study. We thank Prof. Ellen Leffler for proof-

reading this manuscript. JRC-P thanks the support of Fondecyt regular (No 1190652).

REFERENCES

1. Dalmolin TV, De Lima-morales D, Barth AL. Plasmid-mediated colistin resistance: what do we know? *J Infect.* 2018;1:16–22.
2. Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. *Lancet Infect Dis.* 2016;16:161–8.
3. Quiroga C, Nastro M, Di Conza J. Current scenario of plasmid-mediated colistin resistance in Latin America. *Rev Argent Microbiol.* 2018;23:1–8.
4. Sun J, Zhang H, Liu YH, Feng Y. Towards understanding MCR-like colistin resistance. *Trends Microbiol.* 2018;9:1–15.
5. Legarraga P, Wozniak A, Prado S, Estrella L. First report in Chile of a clinical isolate of *Escherichia coli* resistant to colistin harbouring the *mcr-1* gene. *Rev Chil Infectol.* 2018;35:453–4.
6. Clinical and Laboratory Standards Institute. CLSI. Performance standards for antimicrobial susceptibility testing. In: CLSI supplement M100. 27th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.
7. Xia L, Liu Y, Xia S, et al. Prevalence of ST1193 clone and IncI1/ST16 plasmid in *E. coli* isolates carrying *bla*_{CTX-M-55} gene from urinary tract infections patients in China. *Sci Rep.* 2017;7:1–8.
8. Huang B, He Y, Ma X, et al. Promoter variation and gene expression of *mcr-1*-harboring plasmids in clinical isolates of *Escherichia coli* and *Klebsiella pneumoniae* from a Chinese Hospital. *Antimicrob Agents Chemother.* 2018;62:e00018–18.
9. Blanco M, Blanco JE, Mora A, et al. Serotypes, virulence genes, and intimin types of Shiga toxin (verotoxin)-producing *Escherichia coli* isolates from healthy sheep in Spain. *J Clin Microbiol.* 2003;41:1351–6.
10. Budić M, Rijavec M, Petkovšek Ž, Žgur-Bertok D. *Escherichia coli* bacteriocins: antimicrobial efficacy and prevalence among isolates from patients with bacteraemia. *PLoS One.* 2011;6.
11. Russo TA, McFadden CD, Carlino-MacDonald UB, Beanan JM, Barnard TJ, Johnson JR. IroN functions as a siderophore receptor and is a urovirulence factor in an extraintestinal pathogenic isolate of *Escherichia coli*. *Infect Immun.* 2002;70:7156–60.
12. Johnson TJ, Wannemuehler YM, Nolan LK. Evolution of the iss gene in *Escherichia coli*. *Appl Environ Microbiol.* 2008;74:2360–9.
13. Schembri M, Zakour N, Phan M-D, Forde B, Stanton-Cook M, Beatson S. Molecular characterization of the multidrug resistant *Escherichia coli* ST131 clone. *Pathogens.* 2015;4:422–30.
14. Roer L, Hansen F, Frølund Thomsen MC, et al. WGS-based surveillance of third-generation cephalosporin-resistant *Escherichia coli* from bloodstream infections in Denmark. *J Antimicrob Chemother.* 2017;72:1922–9.
15. Wang R, Van Dorp L, Shaw LP, et al. The global distribution and spread of the mobilized colistin resistance gene *mcr-1*. *Nat Commun.* 2018;9:1–9.
16. Tijet N, Faccone D, Rapoport M, et al. Molecular characteristics of *mcr-1*-carrying plasmids and new *mcr-1* variant recovered from polyclonal clinical *Escherichia coli* from Argentina and Canada. *PLoS One.* 2017;12:1–13.
17. Wang Q, Li Z, Lin J, Wang X, Deng X, Feng Y. Complex dissemination of the diversified *mcr-1*-harbouring plasmids in *Escherichia coli* of different sequence types. *Oncotarget.* 2016;7:82112–22.
18. Rozwandowicz M, Brouwer MSM, Fischer J, et al. Plasmids carrying antimicrobial resistance genes in Enterobacteriaceae. *J Antimicrob Chemother.* 2018;73:1121–237.
19. Tatusova T, Dicuccio M, Badretdin A, et al. NCBI prokaryotic genome annotation pipeline. *Nucleic Acids Res.* 2016;44:6614–24.
20. González G, Mella S, Zemelman R, Bello H, Domínguez M. Integrones y cassettes genéticos de resistencia: Estructura y rol frente a los antibacterianos. *Rev Med Chil.* 2004;132:619–26.
21. Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. *Drug Resist Updat.* 2010;13:151–71.
22. Bagel S, Hüllen V, Wiedemann B, Heisig P. Impact of *gyrA* and *parC* mutations on quinolone resistance, doubling time, and supercoiling degree of *Escherichia coli*. *Antimicrob Agents Chemother.* 1999;43:868–75.
23. Roosaare M, Puustusmaa M, Möls M, Vaher M, Remm M. PlasmidSeeker: identification of known plasmids from bacterial whole genome sequencing reads. *PeerJ.* 2018;6:e4588.